Chantix Related Published Studies
Well-designed clinical trials related to Chantix (Varenicline)
Varenicline reduces alcohol self-administration in heavy-drinking smokers. [2009.07.15]
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. [2009.06]
Varenicline for smoking cessation: a placebo-controlled, randomized study. [2009.04]
Varenicline for smoking cessation: A placebo-controlled, randomized study. [2009.01.23]
Varenicline improves mood and cognition during smoking abstinence. [2009.01.15]
Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [2009.01]
Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. [2009]
Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. [2008.11]
The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. [2008.07]
Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. [2008.04]
Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. [2007.11]
Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. [2007.06]
A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. [2007.06]
A double-blind study evaluating the long-term safety of varenicline for smoking cessation. [2007.04]
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. [2006.12]
Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. [2006.11]
Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. [2006.11]
Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. [2006.09]
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. [2006.08.14]
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. [2006.08.14]
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. [2006.07.05]
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. [2006.07.05]
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. [2006.07.05]
Well-designed clinical trials possibly related to Chantix (Varenicline)
Relapse prevention interventions for smoking cessation. [2009.01.21]
Nicotine receptor partial agonists for smoking cessation. [2008.07.16]
Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. [2007.05]
An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. [2007.04]
Nicotine receptor partial agonists for smoking cessation. [2007.01.24]
Other research related to Chantix (Varenicline)
Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation: A BENESCO Markov Cost-Effectiveness Analysis. [2009.10.01]
Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. [2009.09]
Varenicline increases striatal dopamine D(2/3) receptor binding in rats. [2009.09]
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. [2009.08.20]
Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. [2009.07]
Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. [2009.06.02]
Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. [2009.06]
Cost-effectiveness of varenicline for smoking cessation. [2009.06]
Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). [2009.06]
Chantix-induced mental status changes in a young healthy female. [2009.05]
Reduced affective symptoms during tobacco dependence treatment with varenicline. [2009.05]
Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. [2009.05]
Combination treatment with varenicline and nicotine replacement therapy. [2009.05]
Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. [2009.04]
The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. [2009.04]
Varenicline-induced mania in a bipolar patient. [2009.03]
Varenicline: a first-line treatment option for smoking cessation. [2009.03]
Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome. [2009.02]
Varenicline: a novel pharmacotherapy for smoking cessation. [2009]
Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. [2009]
Varenicline-associated acute renal failure. [2008.12]
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. [2008.11.10]
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. [2008.11]
The influence of acute varenicline administration on smoking and eating behavior in humans. [2008.11]
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. [2008.10]
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. [2008.09.01]
A longer course of varenicline therapy improves smoking cessation rates. [2008.09]
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. [2008.08]
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. [2008.07.26]
Budgetary Impact of Varenicline in Smoking Cessation in the United Kingdom. [2008.07.11]
Diffuse exanthema in a patient receiving varenicline. [2008.07.01]
Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. [2008.06]
Varenicline may trigger severe hypoglycaemia in Type 1 diabetes. [2008.05]
Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003. [2008.05]
Efficacy and safety of varenicline for smoking cessation. [2008.04]
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. [2008.04]
Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. [2008.04]
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. [2008.01]
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. [2008.01]
Smoking cessation therapy with varenicline. [2008]
Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. [2008]
Tobacco smoking cessation management: integrating varenicline in current practice. [2008]
Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline? [2007.12]
[Varenicline--a new drug for smoking cessation] [2007.11.19]
[New drugs; varenicline] [2007.11.10]
[Varenicline: an aid to smoking cessation therapy] [2007.11]
Smoking cessation: an overview of treatment options with a focus on varenicline. [2007.11]
The cost effectiveness of varenicline for smoking cessation. [2007.10]
Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine. [2007.10]
Varenicline: progress in smoking cessation treatment. [2007.08]
Varenicline: the newest agent for smoking cessation. [2007.07.01]
Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. [2007.05]
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. [2007.03]
[Drug of the month. Varenicline (Champix)] [2007.02]
Varenicline: new treatment with efficacy in smoking cessation. [2007.02]
Varenicline for smoking cessation. [2007.02]
Oral varenicline for smoking cessation. [2007.01]
[Varenicline--a new chance for smokers?] [2007]
The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. [2006.05]
[New tobacco dependence drug: Varenicline, partial agonist of alpha4beta2 acetylcholine-nicotine receptors] [2006]
Varenicline: a review of its use as an aid to smoking cessation therapy. [2006]
Other possibly related research studies
Kicking butts: smoking cessation update. [2007.05]
Smoking cessation: lessons learned from clinical trial evidence. [2007.07]
[Tobacco use prevention and cessation in the dental practice] [2007]
Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions. [2007.03]
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. [2007.03]
A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease. [2007.03]
Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. [2007.02]
Non-nicotinic therapies for smoking cessation. [2007]
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. [2006.12.11]
Pharmacologic interventions for smoking cessation. [2006.03]
Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. [2005.05]
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. [2008.07.15]
|
